Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Sanofi's Rilzabrutinib LUNA 3 Phase 3 Study Met Primary Endpoint In Immune Thrombocytopenia

Author: Benzinga Newsdesk | April 23, 2024 01:41am

Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia

Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential of rilzabrutinib to provide a clinically meaningful benefit to patients living with ITP
Regulatory submissions in the US and EU anticipated by year-end
Rilzabrutinib is one of 12 potential medicines and vaccines in Sanofi's robust immunology pipeline and a testament to Sanofi's ability to successfully accelerate and build a portfolio of next-generation transformative treatments for immune diseases
In addition to ITP, rilzabrutinib is being studied across a variety of immune-mediated diseases including asthma, chronic spontaneous urticaria, prurigo nodularis, IgG4-related disease and warm autoimmune hemolytic anemia

Posted In: SNY